Mizuho raised the firm’s price target on Insmed to $35 from $33 and keeps a Buy rating on the shares following the Q3 report. The firm citers increased confidence in pipeline asset TPIP following the announcement of “encouraging” initial Phase 2 dosing and safety/tolerability data for the target raise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSM: